Risk of ovarian cancer national cancer institute u s. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy3

Cell Line, Tumor Tumor Cells, Cultured Neoplastic Stem Cells

Organisms2

Mice, Nude Vegetables

Diseases51

Ovarian Neoplasms Neoplasms Breast Neoplasms Neoplasms, Glandular and Epithelial Lung Neoplasms Prostatic Neoplasms Carcinoma Neoplasm Metastasis Neoplasm Invasiveness Colonic Neoplasms Cystadenocarcinoma, Serous Neoplasm Recurrence, Local Stomach Neoplasms Colorectal Neoplasms Genetic Predisposition to Disease Disease Progression Pancreatic Neoplasms Adenocarcinoma Uterine Cervical Neoplasms Carcinoma, Non-Small-Cell Lung Neoplasms, Second Primary Urinary Bladder Neoplasms Carcinoma, Squamous Cell Genital Neoplasms, Female Endometrial Neoplasms Rectal Neoplasms Skin Neoplasms Adenocarcinoma, Clear Cell Carcinoma, Small Cell Kidney Neoplasms Melanoma Peritoneal Neoplasms Carcinoma, Endometrioid Head and Neck Neoplasms Adenocarcinoma, Mucinous Liver Neoplasms Neutropenia Neoplasms, Experimental Gastrointestinal Neoplasms Neoplasms, Radiation-Induced Ascites Brain Neoplasms Bone Neoplasms Nausea Thyroid Neoplasms Vomiting Cell Transformation, Neoplastic Esophageal Neoplasms Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Fatigue

Chemicals and Drugs43

Antineoplastic Agents Cisplatin Tumor Markers, Biological Paclitaxel CA-125 Antigen Neoplasm Proteins Antineoplastic Agents, Phytogenic Carboplatin Organoplatinum Compounds Fluorouracil Cancer Vaccines Deoxycytidine DNA, Neoplasm RNA, Messenger Receptors, Estrogen Antimetabolites, Antineoplastic Prostate-Specific Antigen BRCA2 Protein Taxoids Topotecan Tamoxifen BRCA1 Protein Tumor Suppressor Protein p53 Platinum Compounds Antibodies, Monoclonal Receptor, erbB-2 Carcinogens Cyclophosphamide Antibodies, Monoclonal, Humanized Receptors, Progesterone Antineoplastic Agents, Hormonal Antigens, Neoplasm RNA, Small Interfering Antineoplastic Agents, Alkylating Camptothecin Anticarcinogenic Agents Quinazolines Vinblastine Receptor, Epidermal Growth Factor Antibiotics, Antineoplastic Doxorubicin Enzyme Inhibitors Proto-Oncogene Proteins

Analytical, Diagnostic and Therapeutic Techniques and Equipment79

SEER Program Early Detection of Cancer Drug Screening Assays, Antitumor Antineoplastic Combined Chemotherapy Protocols Survival Analysis Clinical Trials as Topic Survival Rate Neoplasm Staging Treatment Outcome Prognosis Registries Incidence Retrospective Studies Disease-Free Survival Follow-Up Studies Risk Factors Combined Modality Therapy Prospective Studies Drug Administration Schedule Risk Assessment Risk Kaplan-Meier Estimate Clinical Trials, Phase III as Topic Chemotherapy, Adjuvant Gene Expression Profiling Questionnaires Xenograft Model Antitumor Assays Odds Ratio Research Design Cohort Studies Multicenter Studies as Topic Radiotherapy Logistic Models Reproducibility of Results Multivariate Analysis Sensitivity and Specificity Infusions, Intravenous Mammography Reverse Transcriptase Polymerase Chain Reaction Patient Selection Confidence Intervals Oligonucleotide Array Sequence Analysis Clinical Trials, Phase II as Topic Neoplasm Grading Mass Screening Predictive Value of Tests Clinical Trials, Phase I as Topic Carcinogenicity Tests Immunohistochemistry Case-Control Studies Polymerase Chain Reaction Maximum Tolerated Dose Blotting, Western Radiotherapy, Adjuvant Neoplasms, Experimental Neoplasm Transplantation Prevalence Radiotherapy Dosage Mastectomy Administration, Oral Lymph Node Excision Drug Evaluation, Preclinical Genetic Testing Epidemiologic Studies Transplantation, Heterologous Mastectomy, Segmental Regression Analysis Feasibility Studies Probability Pilot Projects Drug Evaluation Proportional Hazards Models Flow Cytometry Cross-Sectional Studies Models, Biological Data Collection Tumor Burden Models, Statistical Immunotherapy

Psychiatry and Psychology2

Smoking Cooperative Behavior

Phenomena and Processes27

Drug Resistance, Neoplasm Gene Expression Regulation, Neoplastic Genes, BRCA1 Genetic Predisposition to Disease Risk Time Factors Dose-Response Relationship, Drug Odds Ratio Mutation Sensitivity and Specificity Genes, BRCA2 Cell Proliferation Apoptosis Genotype Cell Survival Diet Maximum Tolerated Dose Germ-Line Mutation Cell Division Cell Cycle DNA Methylation Postmenopause Probability Cell Movement Down-Regulation Microsatellite Repeats Cell Growth Processes

Disciplines and Occupations7

Medical Oncology Biomedical Research Research Design Research Immunohistochemistry Translational Medical Research Radiation Oncology

Anthropology, Education, Sociology and Social Phenomena10

National Cancer Institute (U.S.)National Institutes of Health (U.S.)National Institute for Occupational Safety and Health (U.S.)Quality of Life Government Programs National Heart, Lung, and Blood Institute (U.S.)Age Distribution Forecasting Community Networks Health Education

Technology, Industry, Agriculture1

Humanities1

Quality of Life

Information Science12

SEER Program Survival Rate Registries Incidence Databases, Factual Questionnaires Information Services Databases as Topic Prevalence Community Networks Internet Data Collection

Named Groups7

European Continental Ancestry Group Survivors African Americans Ethnic Groups Research Personnel Hispanic Americans African Continental Ancestry Group

Health Care69

National Cancer Institute (U.S.)National Institutes of Health (U.S.)Academies and Institutes SEER Program Survival Analysis Clinical Trials as Topic Survival Rate Cancer Care Facilities Treatment Outcome Research Support as Topic Registries Incidence Retrospective Studies Disease-Free Survival Follow-Up Studies Risk Factors Age Factors Prospective Studies Risk Assessment Risk American Cancer Society Kaplan-Meier Estimate Clinical Trials, Phase III as Topic Questionnaires Odds Ratio National Institute for Occupational Safety and Health (U.S.)Cohort Studies Multicenter Studies as Topic Institute of Medicine (U.S.)Tissue Banks Logistic Models Reproducibility of Results Multivariate Analysis Pharmacy and Therapeutics Committee Sensitivity and Specificity Patient Selection Confidence Intervals Sex Factors Clinical Trials, Phase II as Topic National Heart, Lung, and Blood Institute (U.S.)Mass Screening Predictive Value of Tests National Health Programs Age Distribution Clinical Trials, Phase I as Topic Congresses as Topic Case-Control Studies Confounding Factors (Epidemiology)Ethnic Groups Prevalence Financing, Government Professional Staff Committees Genetic Testing Epidemiologic Studies Community Networks Practice Guidelines as Topic Regression Analysis Feasibility Studies Probability Pilot Projects Health Education Proportional Hazards Models Cost-Benefit Analysis Cross-Sectional Studies Occupational Exposure Health Planning Guidelines Data Collection Models, Statistical Health Services Accessibility

Geographicals6

United States Canada Delaware Egypt Italy Great Britain

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Psychiatry and Psychology Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Humanities Information Science Named Groups Health Care Geographicals

National Cancer Institute (U.S.)National Institutes of Health (U.S.)Ovarian Neoplasms United States Neoplasms Academies and Institutes SEER Program Antineoplastic Agents Breast Neoplasms Neoplasms, Glandular and Epithelial Early Detection of Cancer Drug Screening Assays, Antitumor Antineoplastic Combined Chemotherapy Protocols Survival Analysis Clinical Trials as Topic Survival Rate Medical Oncology Cancer Care Facilities Lung Neoplasms Prostatic Neoplasms Neoplasm Staging Treatment Outcome Prognosis Research Support as Topic Cell Line, Tumor Registries Incidence Retrospective Studies Cisplatin Tumor Markers, Biological Disease-Free Survival Drug Resistance, Neoplasm Follow-Up Studies Carcinoma Gene Expression Regulation, Neoplastic Paclitaxel Risk Factors CA-125 Antigen Neoplasm Metastasis Neoplasm Invasiveness Colonic Neoplasms Combined Modality Therapy Age Factors Cystadenocarcinoma, Serous Neoplasm Recurrence, Local Stomach Neoplasms Mice, Nude Colorectal Neoplasms Biomedical Research Prospective Studies Drug Administration Schedule Risk Assessment Genes, BRCA1 Genetic Predisposition to Disease Risk American Cancer Society Canada Neoplasm Proteins Disease Progression Pancreatic Neoplasms Antineoplastic Agents, Phytogenic Adenocarcinoma Kaplan-Meier Estimate Time Factors Databases, Factual Dose-Response Relationship, Drug Uterine Cervical Neoplasms Carcinoma, Non-Small-Cell Lung Clinical Trials, Phase III as Topic Chemotherapy, Adjuvant Gene Expression Profiling Questionnaires Xenograft Model Antitumor Assays Odds Ratio Research Design National Institute for Occupational Safety and Health (U.S.)Cohort Studies European Continental Ancestry Group Multicenter Studies as Topic Neoplasms, Second Primary Institute of Medicine (U.S.)Urinary Bladder Neoplasms Tumor Cells, Cultured Carboplatin Tissue Banks Mutation Organoplatinum Compounds Radiotherapy Quality of Life Government Programs Fluorouracil Logistic Models Reproducibility of Results Multivariate Analysis Survivors Cancer Vaccines Pharmacy and Therapeutics Committee Smoking Carcinoma, Squamous Cell Sensitivity and Specificity

No FAQ available that match "risk of ovarian cancer national cancer institute u s"